Research News and Research

RSS

Abbott reports positive interim results from LCIG Phase III open-label study for advanced Parkinson's disease

Interim efficacy and safety results from a long-term, 54-week, Phase III open-label study of Abbott's investigational treatment for advanced Parkinson's disease showed that patients treated with levodopa-carbidopa intestinal gel (LCIG) for 12 weeks reported a decrease in "off" time and an increase in "on" time without troublesome dyskinesias.

9 Jun 2011

Obama administration launches new program to spur health IT innovation

The initiative, announced Wednesday, uses prizes and challenges to encourage accelerated research and development activities in the health IT sector.

9 Jun 2011

Deadline extended for ACO pioneer program

The new deadline is Aug. 19. Meanwhile, in other policy-related news, the White House pushed back against study findings released earlier this week by McKinsey & Co. that as many as 30 percent of companies may stop offering health insurance to their employees and said the president's healthcare plan "will reduce costs overall."

9 Jun 2011

Promising results from VX-770 and VX-809 Phase 2 study for cystic fibrosis

Vertex Pharmaceuticals Incorporated and the Cystic Fibrosis Foundation today announced promising results from an ongoing Phase 2 study evaluating combinations of VX-770 and VX-809, potential medicines designed to treat the defective protein that causes cystic fibrosis.

9 Jun 2011

New vaccine leads to dramatic fall in meningitis A cases

Burkina Faso, Mali, and Niger report the lowest number of confirmed meningitis A cases ever recorded during an epidemic season this year following the successful introduction of a new vaccine that could eliminate the primary cause of the deadly disease from Africa's meningitis belt, announced the Meningitis Vaccine Project (MVP) today, which spearheaded development of the vaccine.

9 Jun 2011

University of Mississippi grants ChromaDex global rights to pterostilbene

ChromaDex Corp. and the University of Mississippi today announced the university has granted the natural products company the exclusive worldwide patent rights to a potential new therapeutic use for pterostilbene (tero-STILL-bean) as an anxiolytic or anti-anxiety agent. ChromaDex' pTeroPure® is an ultra-pure formulation of pterostilbene, a compound found in blueberries and demonstrated to have multiple health benefits.

9 Jun 2011

Lund researchers create nerve cells from human skin

A research breakthrough has proven that it is possible to reprogram mature cells from human skin directly into brain cells, without passing through the stem cell stage. The unexpectedly simple technique involves activating three genes in the skin cells; genes which are already known to be active in the formation of brain cells at the foetal stage.

9 Jun 2011

Synaptophysin controls replacement of vesicles

A University of Wisconsin-Madison research team has solved a 25-year mystery that may lead to better treatments for people with learning deficits and mental retardation.

9 Jun 2011

First Edition: June 9, 2011

Today's headlines include reports from yesterday's action in an Atlanta courtroom where oral arguments were held in an appeal related to the multi-state challenge to the health law.

9 Jun 2011

Celerion earns ANVISA certification to conduct clinical research operations in Belfast, Lincoln

Celerion, the premier provider of innovative early stage drug development solutions, is pleased to announce that its clinical research operations in Belfast, Northern Ireland UK, and its clinical research and bioanalytical services operations in Lincoln, Nebraska USA, have been certified by the Brazilian National Health Surveillance Agency.

9 Jun 2011

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat the defective protein that causes cystic fibrosis.

9 Jun 2011

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Repligen Corporation today reported results for the fourth quarter and fiscal year 2011, ended March 31, 2011.

9 Jun 2011

Foundation for Peripheral Neuropathy to launch first ever national PN research registry

What starts as burning, numbness, pain, and/or tingling in the feet, or hands in some can turn into a debilitating condition. Peripheral Neuropathy (PN), one of the largest and most common neurodegenerative disorders, affects more than 20 million Americans of all races and ethnic backgrounds.

9 Jun 2011

Make antiretroviral therapy 'cornerstone' of HIV prevention

Ahead of the U.N. High Level Meeting on AIDS, AVAC: Global Advocacy for HIV Prevention and multiple signatories in a statement call on governments, advocates and researchers to act on the evidence from HPTN 052 and make antiretroviral therapy a cornerstone of the set of proven strategies we have to prevent and treat HIV.

9 Jun 2011

GeneTex to introduce new Easy-iPSC minicircle DNA vector technology in June

GeneTex, a leading manufacturer of antibodies for research use, is pleased to announce they will be launching several new exciting products in June, including the new Easy-iPSC minicircle DNA vector technology.

9 Jun 2011

IAS calls on leaders to include HIV cure research in global strategy

The International AIDS Society (IAS) in a statement released ahead of the U.N. High Level Meeting on AIDS "calls on leaders to ensure the inclusion of HIV cure research and its global strategy into the international HIV agenda and in all discussions, political decisions and funding strategies."

9 Jun 2011

JDRF, Selecta Biosciences partner to develop type 1 diabetes vaccine

The Juvenile Diabetes Research Foundation (JDRF) and Selecta Biosciences, Inc. announced today that they have established a research collaboration to support Selecta's development of a vaccine technology, which may subsequently help to better treat and potentially prevent type 1 diabetes.

9 Jun 2011

VOA News examines debate over U.N. Women funding levels

VOA News examines advocates' concerns over funding levels for U.N. Women. "The mandate of U.N. Women is large, and some supporters are concerned that its starting budget of $500 million dollars is not enough to promote women and gender equality around the world, especially at the country level.

9 Jun 2011

UNICEF representative highlights humanitarian challenges in Yemen

Geert Cappelaere, UNICEF's representative in Yemen, said the country is facing humanitarian challenges and is "absolutely in dire need of humanitarian assistance," Reuters reports.

9 Jun 2011

Number of new E. coli cases abating but more deaths expected

"Germany reported two more deaths and 300 more E. coli cases Wednesday, but its health minister insisted that new infections were dropping, giving some hope that the world's deadliest E. coli outbreak was abating," Associated Press reports.

9 Jun 2011